Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 278-285 , October 2001

Newer methods of labeling diagnostic agents with Tc-99m

  • Ronnie C. Mease

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ronnie C. Mease, PhD, Department of Diagnostic Radiology, Division of Nuclear Medicine, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD 21201.
    • ,
  • Carol Lambert

References 

  1. Schwochau K. Technetium radiopharmaceuticals: Fundamentals, synthesis, structure, and development. Angew Chem Int Ed Engl. 1994;33:2258–2267
  2. Jurisson S, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev. 1999;99:2205–2218
  3. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptorspecific small-molecule radiopharmaceuticals: Recent developments and encouraging results. Nucl Med Biol. 1997;24:485–498
  4. Liu S, Edwards DS, Barrett JA. 99mTc labeling of highly potent small peptides. Bioconjug Chem. 1997;8:621–636
  5. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235–2268
  6. Lister-James J, Moyer BR, Dean T. Small peptides radiolabeled with 99mTc. Q J Nucl Med. 1996;40:221–233
  7. Griffiths GL, Goldenberg DM, Jones AL, et al. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjug Chem. 1992;3:91–99
  8. Srivastava SC, Mease RC. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Int J Rad Appl Instrum B. 1991;18:589–603
  9. Pietzsch HJ, Spies H, Hoffman S. Lipophilic Tc complexes. VI. Neutral oxotechnetium(V) complexes with monothiol/tridentate coordination. Inorg Chim Acta. 1989;165:163–166
  10. Syhre R, Seifert S, Spies H, et al. Stability versus reactivity of “3+1” mixed-ligand technetium-99m complexes in vitro and in vivo. Eur J Nucl Med. 1998;25:793–796
  11. Hoepping A, Reisgys M, Brust P, et al. TROTEC-1: A new high-affinity ligand for labeling of the dopamine transporter. J Med Chem. 1998;41:4429–4432
  12. Johannsen B, Scheunemann M, Spies H, et al. Technetium(V) and rhenium(V) complexes for 5-HT2A serotonin receptor binding: Structureaffinity considerations. Nucl Med Biol. 1996;23:429–438
  13. Johannsen B, Berger R, Brust P, et al. Structural modification of receptor-binding technetium-99m complexes in order to improve brain uptake. Eur J Nucl Med. 1997;24:316–319
  14. Skaddan MB, Wust FR, Jonson S, et al. Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7alpha-substituted estradiol complexes. Nucl Med Biol. 2000;27:269–278
  15. Skaddan MB, Wust F, Katzenellenbogen JA. Synthesis and binding affinities of novel Re-containing 7a-substituted estradiol complexes: Models for breast cancer imaging agents. J Org Chem. 1999;64:8108–8121
  16. Wust F, Carlson KE, Katzenellenbogen JA, et al. Synthesis and binding affinities of new 17 alpha-substituted estradiol-rhenium “n + 1” mixed-ligand and thioether-carbonyl complexes. Steroids. 1998;63:665–671
  17. Wust F, Skaddan MB, Leibnitz P, et al. Synthesis of novel progestin-rhenium conjugates as potential ligands for the progesterone receptor. Bioorg Med Chem. 1999;7:1827–1835
  18. Bergmann R, Brust P, Scheunemann M, et al. Assessment of the in vitro and in vivo properties of a 99mTc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein. Nucl Med Biol. 2000;27:135–141
  19. Alberto R, Schibli R, Egli A, et al. A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of [99mTc(OH2)3(CO)3]+ from from [99mTcO4]− in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987–7988
  20. Alberto R, Schibli R, Schubiger PA, et al. First application of fac-[99mTc(OH2)3(CO)3]+ in bioorganometallic chemistry: Design, structure, and in vitro affinity of a 5-HT1A receptor ligand labeled with 99MTc. J Am Chem Soc. 1999;121:6076–6077
  21. Schibli R, La Bella R, Alberto R, et al. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of (99m)Tc(I)-tricarbonyl complexes: A hint for the future functionalization of biomolecules. Bioconjug Chem. 2000;11:345–351
  22. Schibli R, Katti KV, Higginbotham C, et al. In vitro and in vivo evaluation of bidentate, water-soluble phosphine ligands as anchor groups for the organometallic fac-[99mTc(CO)3]+-core. Nucl Med Biol. 1999;26:711–716
  23. Pietzsch HJ, Gupta A, Reisgys M, et al. Chemical and biological characterization of technetium(I) and rhenium(I) tricarbonyl complexes with dithioether ligands serving as linkers for coupling the Tc(CO)3 and Re(CO)3 moieties to biologically active molecules. Bioconjug Chem. 2000;11:414–424
  24. (abstr) Marmion ME, Bugaj JE, Schmidt MA, et al. Preparation and biological evaluation of 99mTc(I)-carbonyl labeled octreotate conjugates. J Nucl Med. 2000;41:156P
  25. Alberto R, Schibli R, Egli A, et al. Steps towards [(C5-Me5)TcO3] novel synthesis of [C5Me5)Tc(CO)3] from [{Tc(m3-OH)(CO)3}4] and oxidation of [(C5Me5)M(CO)3] (M = Tc, Re) with Br2. Polyhedron. 1998;17:1133–1140
  26. Skerra A, Pfitzinger I, Pluckthun A. The functional expression of antibody Fv fragments in Escherichia coli: Improved vectors and a generally applicable purification technique. Biotechnology (N Y). 1991;9:273–278
  27. Waibel R, Alberto R, Willunda J, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol. 1999;17:897–901
  28. Minutolo F, Katzenellenbogen JA. Boronic acids in the three-component synthesis of carbon-substituted cyclopentadienyl tricarbonyl rhenium complexes. J Am Chem Soc. 1998;120:13264–13265
  29. Minutolo F, Katzenellenbogen JA. A convenient three-component synthesis of substituted cyclopentadienyl tricarbonyl rhenium complexes. J Am Chem Soc. 1998;120:4514–4515
  30. Minutolo F, Katzenellenbogen JA. Three-component synthesis of substituted h5-cyclopentadienyl tricarbonylrhenium complexes: Scope, limitations, and mechanistic interpretations. Organometallics. 1998;18:2519–2530
  31. Spradau TW, Edwards WB, Anderson CJ, et al. Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricar-bonyltechnetiumlabeled octreotide. Nucl Med Biol. 1999;26:1–7
  32. Spradau TW, Katzenellenbogen JA. Preparation of cyclopentadienyl tricarbonylrhenium complexes using a double ligand transfer reaction. Organometallics. 1998;17:2009–2017
  33. Spradau TW, Katzenellenbogen JA. Protein and peptide labeling with (cyclopentadienyl)tricarbonyl rhenium and technetium. Bioconjug Chem. 1998;9:765–772
  34. Chi DY, O'Neil JP, Anderson CJ, et al. Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J Med Chem. 1994;37:928–937
  35. Chi DY, Katzenellenbogen JA. Selective formation of heterodimeric bis-bidentate aminothiol oxometal complexes of rhenium(V). J Am Chem Soc. 1993;115:7045–7046
  36. Hom RK, Chi DY, Katzenellenbogen JA. Heterodimeric bis(amino thiol) complexes of oxorhenium(V) that mimic the structure of steroid hormones. Synthesis and stereochemical issues. J Org Chem. 1996;61:2624–2631
  37. Hom RK, Katzenellenbogen JA. Synthesis of a tetradentate oxorhenium(V) complex mimic of a steroidal estrogen. J Org Chem. 1997;62:6290–6297
  38. Trejtnar F, Laznicek M, Laznickova A, et al. Pharmacokinetics and renal handling of 99mTc-labeled peptides. J Nucl Med. 2000;41:177–182
  39. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022–2028
  40. Liu S, Edwards DS, Looby RJ, et al. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands. Bioconjug Chem. 1996;7:63–71
  41. Edwards DS, Liu S, Barrett JA, et al. New and versatile ternary ligand system for technetium radiopharmaceuticals: Water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamidemodified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. Bioconjug Chem. 1997;8:146–154
  42. Edwards DS, Liu S, Harris AR, et al. 99mTc-labeling of hydrazones of a hydrazinonicotinamide conjugated cyclic peptide. Bioconjug Chem. 1999;10:803–807
  43. Liu S, Edwards DS, Harris AR. A novel ternary ligand system for 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjug Chem. 1998;9:583–595
  44. Edwards DS, Liu S, Ziegler MC, et al. RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging. Bioconjug Chem. 1999;10:884–891
  45. Decristoforo C, Mather SJ. 99m-Technetium-labelled peptide-HYNIC conjugates: Effects of lipophilicity and stability on biodistribution. Nucl Med Biol. 1999;26:389–396
  46. Harris TD, Sworin M, Williams N, et al. Synthesis of stable hydrazones of a hydrazinonicotinyl-modified peptide for the preparation of 99mTc-labeled radiopharmaceuticals. Bioconjug Chem. 1999;10:808–814
  47. Kasina S, Rao TN, Srinivasan A, et al. Development and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J Nucl Med. 1991;32:1445–1451
  48. Blend MJ, Hyun H, Patel B, et al. Radioimmunoscintigraphy in patients with early stage cutaneous malignant melanoma. J Nucl Med. 1996;37:252–257
  49. Balaban EP, Walker BS, Cox JV, et al. Detection and staging of small cell lung carcinoma with a technetium-labeled monoclonal antibody. A comparison with standard staging methods. Clin Nucl Med. 1992;17:439–445
  50. Kasina S, Sanderson JA, Fitzner JN, et al. Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate). Bioconjug Chem. 1998;9:108–117
  51. Liu S, Edwards DS, Looby RJ, et al. Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: Effects of chelators on properties of [99mTc]chelator-peptide conjugates. Bioconjug Chem. 1996;7:196–202
  52. Karra SR, Schibli R, Gali H, et al. 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjug Chem. 1999;10:254–260
  53. Baidoo KE, Scheffel U, Stathis M, et al. High-affinity no-carrieradded 99mTc-labeled chemotactic peptides for studies of inflammation in vivo. Bioconjug Chem. 1998;9:208–217
  54. Kao CH, Baidoo KE, Lever SZ. Validation and application of a solid phase chemistry method for preparation of high effective specific-activity technetium-99m radiopharmaceuticals. Nucl Med Biol. 1997;24:499–505
  55. Dunn-Dufault R, Pollak A, Thornback JR, et al. Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technology. Bioconjug Chem. 1999;10:832–837
  56. Pollak A, Roe DG, Pollock CM, et al. A convenient method of preparing high specific-activity technetium complexes using thiolcontaining chelators adsorbed on gold. J Am Chem Soc. 1999;121:11593–11594
  57. Qaim SM. Production of high purity 94mTc for positron emission tomography studies. Nucl Med Biol. 2000;27:323–328
  58. Stone CK, Christian BT, Nickles RJ, et al. Technetium 94m-labeled methoxyisobutyl isonitrile: Dosimetry and resting cardiac imaging with positron emission tomography. J Nucl Cardiol. 1994;1:425–433
  59. Nickles RJ, Nunn AD, Stone CK, et al. Technetium-94m-teboroxime: Synthesis, dosimetry and initial PET imaging studies. J Nucl Med. 1993;34:1058–1066
  60. (abstr) Szajek L, Kung H, Plascjak P, et al. Comparison of [94mTc]- and [99mTc]trodat-I as imaging agents for the dopamine transporter. J Labelled Compd Radiopharm. 1999;42:S45–S47
  61. Griffiths GL, Goldenberg DM, Roesch F, et al. Radiolabeling of an anti-carcinoembryonic antigen antibody Fab' fragment (CEA-Scan) with the positron-emitting radionuclide Tc-94m. Clin Cancer Res. 1999;5:3001s–3003s

PII: S0001-2998(01)80007-6

doi: 10.1053/snuc.2001.26182

Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 278-285 , October 2001

Article Tools